Prothena Corporation PLC to Post Q2 2017 Earnings of ($0.64) Per Share, Jefferies Group Forecasts (PRTA)

Prothena Corporation PLC (NASDAQ:PRTA) – Analysts at Jefferies Group issued their Q2 2017 earnings per share (EPS) estimates for Prothena Corporation PLC in a report issued on Monday. Jefferies Group analyst M. Yee expects that the biotechnology company will post earnings of ($0.64) per share for the quarter. Jefferies Group has a “Buy” rating and a $100.00 price target on the stock. Jefferies Group also issued estimates for Prothena Corporation PLC’s Q3 2017 earnings at ($1.48) EPS, Q4 2017 earnings at ($1.59) EPS, FY2017 earnings at ($4.72) EPS and FY2018 earnings at ($6.72) EPS.

Prothena Corporation PLC (NASDAQ:PRTA) last announced its quarterly earnings data on Tuesday, May 9th. The biotechnology company reported ($0.99) earnings per share for the quarter, beating the consensus estimate of ($1.32) by $0.33. Prothena Corporation PLC had a negative net margin of 16,012.49% and a negative return on equity of 39.67%. The firm had revenue of $0.26 million for the quarter, compared to analyst estimates of $0.26 million. During the same quarter in the prior year, the business earned ($0.81) earnings per share. The business’s quarterly revenue was down 3.7% compared to the same quarter last year.

ILLEGAL ACTIVITY NOTICE: This article was first reported by Markets Daily and is the sole property of of Markets Daily. If you are reading this article on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright legislation. The original version of this article can be accessed at https://www.themarketsdaily.com/2017/08/08/prothena-corporation-plc-to-post-q2-2017-earnings-of-0-64-per-share-jefferies-group-forecasts-prta-updated-updated-updated.html.

Several other equities research analysts have also commented on PRTA. Oppenheimer Holdings, Inc. reissued a “buy” rating on shares of Prothena Corporation PLC in a research note on Wednesday, March 22nd. Wedbush reissued an “outperform” rating and set a $77.00 price objective on shares of Prothena Corporation PLC in a research note on Monday, April 3rd. Piper Jaffray Companies initiated coverage on shares of Prothena Corporation PLC in a research note on Wednesday, April 12th. They set an “overweight” rating and a $69.00 price objective on the stock. Cantor Fitzgerald initiated coverage on shares of Prothena Corporation PLC in a research note on Wednesday, April 12th. They set an “overweight” rating and a $86.00 price objective on the stock. Finally, Zacks Investment Research raised shares of Prothena Corporation PLC from a “hold” rating to a “buy” rating and set a $59.00 price objective on the stock in a research note on Tuesday, April 18th. Two research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. Prothena Corporation PLC currently has a consensus rating of “Buy” and a consensus price target of $77.38.

Shares of Prothena Corporation PLC (PRTA) opened at 62.29 on Thursday. The company has a 50 day moving average of $53.94 and a 200-day moving average of $52.72. Prothena Corporation PLC has a 12-month low of $40.58 and a 12-month high of $68.18. The firm’s market cap is $2.37 billion.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Bank of Montreal Can raised its stake in shares of Prothena Corporation PLC by 6.7% in the second quarter. Bank of Montreal Can now owns 1,858 shares of the biotechnology company’s stock valued at $100,000 after buying an additional 117 shares during the period. Ameritas Investment Partners Inc. acquired a new stake in shares of Prothena Corporation PLC during the first quarter valued at about $167,000. Stifel Financial Corp acquired a new stake in shares of Prothena Corporation PLC during the first quarter valued at about $224,000. Karp Capital Management Corp acquired a new stake in shares of Prothena Corporation PLC during the first quarter valued at about $243,000. Finally, OMERS ADMINISTRATION Corp acquired a new stake in shares of Prothena Corporation PLC during the first quarter valued at about $273,000.

In other news, Director Dennis J. Selkoe sold 3,500 shares of the business’s stock in a transaction that occurred on Friday, July 7th. The shares were sold at an average price of $58.11, for a total transaction of $203,385.00. Following the completion of the transaction, the director now directly owns 6,345 shares of the company’s stock, valued at $368,707.95. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Karin L. Walker sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, April 17th. The shares were sold at an average price of $52.25, for a total transaction of $261,250.00. Following the transaction, the insider now directly owns 3,000 shares of the company’s stock, valued at $156,750. The disclosure for this sale can be found here. 3.10% of the stock is owned by insiders.

Prothena Corporation PLC Company Profile

Prothena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company’s clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).

Earnings History and Estimates for Prothena Corporation PLC (NASDAQ:PRTA)

Receive News & Ratings for Prothena Corporation PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena Corporation PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply